<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30302857</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1349-7006</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>09</Day>                    </PubDate>                </JournalIssue>                <Title>Cancer science</Title>                <ISOAbbreviation>Cancer Sci.</ISOAbbreviation>            </Journal>            <ArticleTitle>Primary breast diffuse large B-cell lymphoma in the rituximab era: therapeutic modalities and patterns of failure.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.13828</ELocationID>            <Abstract>                <AbstractText>Primary breast diffuse large B-cell lymphoma(PB-DLBCL)Â is a rare subtype of DLBCL with limited data on patterns of failure. This multicenter study aimed to define the optimum treatment strategy and patterns of failure for PB-DLBCL patients. We retrospectively reviewed data on 108 PB-DLBCL patients from 21 Chinese medical centers. Only patients with localized disease (involvement of breast and localized lymph nodes) were included. After a median follow-up of 3.2 years, 32% of patients developed progression or relapse. A continuous pattern of relapse was observed, characterized by frequent late relapses in the contralateral breast and central nervous system(CNS). Although rituximab significantly reduced the overall cumulative risk of progression or relapse(5-year cumulative risk 57% vs 24%, P=0.029), it had limited effect on the reduction of breast relapse(P=0.46). Consolidative radiotherapy significantly decreased the risk of breast relapse, even in the subgroup of patients treated with rituximab (5-year cumulative risk 21.2% vs 0%, P=0.012). A continuous risk of CNS progression or relapse up to 8.2 years from diagnosis was observed (10-year cumulative risk 28.3%), with a median time to CNS relapse of 3.1 years. Neither rituximab nor prophylactic intrathecal chemotherapy significantly decreased the risk of CNS relapse. In summary, our study indicates that PB-DLBCL has a continuous pattern of relapse, especially with frequent late relapses in the CNS and contralateral breast. Rituximab and RT confer complementary benefit in the reduction of relapse. However, neither the addition of rituximab nor prophylactic intrathecal chemotherapy could effectively prevent CNS relapse for PB-DLBCL patients. This article is protected by copyright. All rights reserved.</AbstractText>                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Hu</LastName>                    <ForeName>Shaoxuan</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences&amp; Peking Union Medical College, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Song</LastName>                    <ForeName>Yuqin</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital &amp; Institute, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sun</LastName>                    <ForeName>Xiuhua</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>The 2nd hospital of Dalian Medical University, Dalian, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Su</LastName>                    <ForeName>Liping</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer hospital of Shanxi province, Taiyuan, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Wei</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences&amp; Peking Union Medical College, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jia</LastName>                    <ForeName>Jing</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital &amp; Institute, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bai</LastName>                    <ForeName>Ou</ForeName>                    <Initials>O</Initials>                    <AffiliationInfo>                        <Affiliation>The First Hospital of Jilin University, Jilin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Sheng</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences&amp; Peking Union Medical College, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liang</LastName>                    <ForeName>Rong</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Xijing Hospital, The Fourth Military Medical University, Xi'an, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Xiaoling</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Liaoning Cancer Hospital and Institute, Shenyang, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Huilai</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gao</LastName>                    <ForeName>Yuhuan</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Weijing</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>307 Hospital of Chinese People's Liberation Army, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xiao</LastName>                    <ForeName>Xiubin</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>307 Hospital of Chinese People's Liberation Army, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bao</LastName>                    <ForeName>Huizheng</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Jilin Cancer Hospital, Changchun, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Ningju</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>General Hospital of Ningxia Medical University, Yinchuan, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ren</LastName>                    <ForeName>Hanyun</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University First Hospital, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cen</LastName>                    <ForeName>Xinan</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University First Hospital, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Shun'e</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Xinjiang Cancer Hospital, Wulumuqi, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhao</LastName>                    <ForeName>Yu</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>The General Hospital of Chinese People's Liberation Army, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Yinan</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>The People's Hospital of Tangshan City, Tangshan, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Yalan</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Baotou Cancer Hospital, Baotou, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Aichun</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>The Third Hospital of Haerbin Medical University, Haerbin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Jingwen</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Beijing Tongren Hospital, Capital Medical University, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shi</LastName>                    <ForeName>Yuankai</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences&amp; Peking Union Medical College, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yuan</LastName>                    <ForeName>Ming</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Illinois Institute of Technology, 3001 s Michigan Ave. Unit 601, Chicago, Illinois, 60616, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Yufu</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>He</LastName>                    <ForeName>Xiaohui</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences&amp; Peking Union Medical College, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>09</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Cancer Sci</MedlineTA>            <NlmUniqueID>101168776</NlmUniqueID>            <ISSNLinking>1347-9032</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">breast</Keyword>            <Keyword MajorTopicYN="N">diffuse large B-cell lymphoma</Keyword>            <Keyword MajorTopicYN="N">radiotherapy</Keyword>            <Keyword MajorTopicYN="N">relapse</Keyword>            <Keyword MajorTopicYN="N">rituximab</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30302857</ArticleId>            <ArticleId IdType="doi">10.1111/cas.13828</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>